CA3125345A1 - Anti-tcr antibody molecules and uses thereof - Google Patents
Anti-tcr antibody molecules and uses thereof Download PDFInfo
- Publication number
- CA3125345A1 CA3125345A1 CA3125345A CA3125345A CA3125345A1 CA 3125345 A1 CA3125345 A1 CA 3125345A1 CA 3125345 A CA3125345 A CA 3125345A CA 3125345 A CA3125345 A CA 3125345A CA 3125345 A1 CA3125345 A1 CA 3125345A1
- Authority
- CA
- Canada
- Prior art keywords
- subfamily
- cancer
- cells
- domain
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788497P | 2019-01-04 | 2019-01-04 | |
| US62/788,497 | 2019-01-04 | ||
| US201962803893P | 2019-02-11 | 2019-02-11 | |
| US62/803,893 | 2019-02-11 | ||
| PCT/US2020/012162 WO2020142672A2 (en) | 2019-01-04 | 2020-01-03 | Anti-tcr antibody molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3125345A1 true CA3125345A1 (en) | 2020-07-09 |
Family
ID=71407087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3125345A Pending CA3125345A1 (en) | 2019-01-04 | 2020-01-03 | Anti-tcr antibody molecules and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220064255A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3906057A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7700039B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113543807A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020204686A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3125345A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2595980B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020142672A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119954959A (zh) | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| CN115003698A (zh) * | 2019-11-14 | 2022-09-02 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| EP4185320A4 (en) * | 2020-07-23 | 2025-10-08 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| IL300505A (en) | 2020-08-10 | 2023-04-01 | Janssen Biotech Inc | Materials and methods for the production of biologically engineered virus-specific lymphocytes |
| UY39415A (es) | 2020-09-11 | 2022-03-31 | Janssen Biotech Inc | Métodos y composiciones para modular la inmunidad mediada por cadenas beta |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| IL301242A (en) * | 2020-09-11 | 2023-05-01 | Janssen Biotech Inc | Multi-specific immune targeting molecules and uses thereof |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| CN115820697B (zh) * | 2022-09-23 | 2024-07-30 | 中国海洋大学 | 一种免疫细胞及其制备方法和应用 |
| CN120897930A (zh) * | 2022-12-27 | 2025-11-04 | 耶鲁大学 | TCR-Vβ特异性治疗性分子及其用途 |
| WO2024140981A1 (zh) * | 2022-12-30 | 2024-07-04 | 上药生物治疗(香港)有限公司 | 细胞原位分泌抗体及其用途 |
| EP4683651A2 (en) * | 2023-03-21 | 2026-01-28 | Marengo Therapeutics, Inc. | Tcr targeting molecules and uses thereof |
| WO2024197296A1 (en) | 2023-03-23 | 2024-09-26 | Bodhi Bio Llc | Compositions and methods for antigen-specific therapy |
| CN121487747A (zh) * | 2023-04-27 | 2026-02-06 | 马伦戈治疗公司 | 使用与tcr结合的分子的组合疗法 |
| US20250074966A1 (en) * | 2023-08-31 | 2025-03-06 | Adaptive Biotechnologies Corporation | Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis |
| IL326971A (en) * | 2023-09-05 | 2026-05-01 | Michele Pitaro | Single-chain variable fragment and molecules derived therefrom that bind the trvb5-1 fragment of the β chain of the human T-cell receptor |
| WO2026011097A1 (en) * | 2024-07-03 | 2026-01-08 | Yale University | Antibody drug conjugates comprising tcr-vbeta specific therapeutic molecules and uses thereof |
| WO2026026858A1 (en) * | 2024-07-30 | 2026-02-05 | Biomap (Suzhou) Intelligent Technology Limited | Dsg2 antibody and uses thereof |
| CN120064640B (zh) * | 2025-01-15 | 2026-01-23 | 中牧实业股份有限公司 | 一种猪细小病毒vp2双抗体夹心定量检测试剂盒及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766947A (en) * | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| JPH0787994A (ja) * | 1993-04-30 | 1995-04-04 | Sumitomo Electric Ind Ltd | T細胞抗原受容体Vβ22に対するモノクローナル抗体及びその製造方法 |
| NZ330995A (en) * | 1996-10-04 | 2000-12-22 | Univ Jefferson | Generation of T cells mediating an immune response and use for treating cancer |
| WO2007042809A2 (en) * | 2005-10-11 | 2007-04-19 | Domantis Limited | Antibody polypeptide library screening and selected antibody polypeptides |
| US20130273089A1 (en) * | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
| CN122399016A (zh) * | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| US10647768B2 (en) * | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| HRP20191800T1 (hr) * | 2015-05-13 | 2019-12-27 | Ablynx N.V. | Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti |
| KR20180020202A (ko) * | 2015-06-01 | 2018-02-27 | 메디진 이뮤노테라피스 게엠바하 | T 세포 수용체 특이적 항체 |
| WO2017040930A2 (en) * | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| CN110177803A (zh) * | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| WO2020010250A2 (en) * | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
-
2020
- 2020-01-03 JP JP2021539095A patent/JP7700039B2/ja active Active
- 2020-01-03 GB GB2109794.4A patent/GB2595980B/en active Active
- 2020-01-03 EP EP20736073.6A patent/EP3906057A4/en active Pending
- 2020-01-03 AU AU2020204686A patent/AU2020204686A1/en not_active Abandoned
- 2020-01-03 CN CN202080018799.0A patent/CN113543807A/zh active Pending
- 2020-01-03 CA CA3125345A patent/CA3125345A1/en active Pending
- 2020-01-03 WO PCT/US2020/012162 patent/WO2020142672A2/en not_active Ceased
-
2021
- 2021-07-02 US US17/366,638 patent/US20220064255A1/en not_active Abandoned
-
2025
- 2025-06-20 AU AU2025204695A patent/AU2025204695A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020204686A1 (en) | 2021-07-22 |
| US20220064255A1 (en) | 2022-03-03 |
| GB2595980A (en) | 2021-12-15 |
| GB202109794D0 (en) | 2021-08-18 |
| AU2025204695A1 (en) | 2025-09-04 |
| WO2020142672A3 (en) | 2020-08-20 |
| CN113543807A (zh) | 2021-10-22 |
| WO2020142672A2 (en) | 2020-07-09 |
| EP3906057A4 (en) | 2022-09-14 |
| JP2022524692A (ja) | 2022-05-10 |
| EP3906057A2 (en) | 2021-11-10 |
| GB2595980B (en) | 2023-06-14 |
| JP7700039B2 (ja) | 2025-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7700039B2 (ja) | 抗tcr抗体分子およびその使用 | |
| AU2020384369B2 (en) | Anti-TCR antibody molecules and uses thereof | |
| US20250034217A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
| JP7832892B2 (ja) | Lilrb1ベースのキメラ抗原受容体 | |
| KR102483822B1 (ko) | 태그된 키메라 이펙터 분자 및 그의 리셉터 | |
| JP7033549B2 (ja) | 細胞に基づくネオ抗原ワクチンおよびその使用 | |
| JP7146397B2 (ja) | 改変γδT細胞 | |
| JP2020058380A (ja) | キメラ抗原受容体及びその製造方法 | |
| JP2021534802A (ja) | 複数のhla−gアイソフォームに対するキメラ抗原レセプター | |
| KR20180082493A (ko) | Traf-유도 도메인을 함유하는 키메라 수용체 및 관련 조성물 및 방법 | |
| JP2020530294A (ja) | 遺伝子操作された細胞を調製するための方法および組成物 | |
| US20230108300A1 (en) | Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease | |
| KR20230084470A (ko) | 면역 세포 기능의 향상 | |
| WO2025213573A1 (zh) | 细胞免疫疗法的组合物和方法 | |
| JP2026507388A (ja) | 新規cd19標的化ポリペプチドおよびcd19標的免疫療法 | |
| KR20260013488A (ko) | 면역 이펙터 세포 및 이의 용도 | |
| WO2024193714A1 (zh) | 细胞免疫疗法的组合物和方法 | |
| KR20230019414A (ko) | 항-cd39 항체 및 입양 세포 요법을 포함하는 조합 요법 | |
| RU2795454C2 (ru) | Способы и композиции для получения генно-инженерных клеток | |
| US20250092363A1 (en) | Placenta-derived allogeneic car-t cells and uses thereof | |
| CN121548589A (zh) | 细胞免疫疗法的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250311 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250710 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250714 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250728 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250728 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260216 |